|
| Details |
Case Code: CLIBE067
|
| Case Length: 02 pages |
| Period: -- |
| Pub Date: 2005 |
| Teaching Note:Not Available |
| Subject :Business Environment |
| Price:Rs.100 |
| Organization :-- |
| Industry :Pharma & Biotech |
| Countries : -- |
|
|
|
|
The Issue of Drug Price Control * |
|
|
|
|
|
|
| This case discusses the issue of the proposed National Pharmaceutical Policy, 2006, the new drug price control policy in India. The pharma industry wants competition-based price monitoring instead of cost-based price control. However, the government is keen to add another 354 drugs to the list of drugs under price control. |
| Buy Now |
| To download this case click on the button below, and select the case from the list of available cases: |
OR
 |
|
|
| |
|
| Introduction |
On August 18, 2006, it was reported that pharmaceutical industry representatives had voluntarily agreed to restrict margins on unbranded generic drugs to 15% for wholesalers and 35% for retailers. It was expected that this move could bring down the prices of most unbranded generic drugs by 50% to 60%, with effect from October 02, 2006. The government was expected to issue a notification in this regard under the Drug Price Control Order, 1995 (DPCO, 1995).
This decision was one of the outcomes of a meeting, held on August 17, 2006, between the Union minister for Chemicals and Fertilizers, Ram Vilas Paswan and pharmaceutical industry representatives, to discuss various issues and proposals related to the proposed National Pharmaceutical Policy, 2006...
. |
Keywords |
|
Drug Price Control Order, 1995 (DPCO, 1995), India, Pharmaceutical Industry, unbranded generic drugs, trade margins, wholesalers, retailers, competition-based price monitoring, National List of Essential Medicines, Union minister for Chemicals and Fertilizers, Ram Vilas Paswan, National Pharmaceutical Policy 2006
* This caselet is intended for use only in class discussions.
** More comprehensive case studies are priced at Rs.200 to Rs.700 (US $5 to US
$16) per copy.
|
|
|
|
